SCHEMBL8220146

SCHEMBL8220146

CCCc1ccc2c(cnn2C)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 2/20 0.59
TCF7 P36402 1/20 0.59
MPO P05164 1/20 0.46
CCNC P24863 1/20 0.43
HTR2A P28223 1/20 0.43
CDK8 P49336 1/20 0.43
PASK Q96RG2 1/20 0.43
CDK19 Q9BWU1 1/20 0.43
TRPM5 Q9NZQ8 1/20 0.43
CACNA1H O95180 8/20 0.42
DRD4 P21917 3/20 0.42
SIGMAR1 Q99720 3/20 0.42
TMEM97 Q5BJF2 2/20 0.42
TRPA1 O75762 1/20 0.41
KDM2B Q8NHM5 1/20 0.41
CACNA1G O43497 3/20 0.40
CACNA1I Q9P0X4 3/20 0.40
CDC7 O00311 1/20 0.40
CDH1 P12830 1/20 0.40
TCF4 P15884 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19991900 0.90 CTNNB1 (0.57) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL14402843 0.89 CTNNB1 (0.56) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL13548299 0.88 CTNNB1 (0.47) CTNNB1TCF7MPOCCNCCDK8
SCHEMBL8179108 0.86 CTNNB1 (0.55) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL13476250 0.85 CTNNB1 (0.58) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL31638366 0.85 CTNNB1 (0.58) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL31638220 0.85 CTNNB1 (0.58) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL6340738 0.82 CTNNB1 (0.56) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL13547918 0.81 CTNNB1 (0.51) CTNNB1TCF7MPOCCNCHTR2A
SCHEMBL16406917 0.81 CTNNB1 (0.54) CTNNB1TCF7MPOCCNCHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof MAZE THERAPEUTICS, INC. (US) 2023-11-14 US disclosed
WO-2022198196-A1 INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2022-09-22 WO disclosed
US-8344138-B2 Triazinedione derivatives as GABAB receptor modulators ADDEX PHARMA S.A. (CH) 2013-01-01 US disclosed
WO-2007139856-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814367-B2 Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof GYS2, GYS1, PYGL CTNNB1 899/4885TCF7 3235/4885MPO 3947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.